Omeros (NASDAQ:OMER - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $0.40 million for the quarter.
Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Omeros Trading Up 3.4%
OMER traded up $0.11 during mid-day trading on Monday, hitting $3.32. 2,093,206 shares of the stock were exchanged, compared to its average volume of 654,615. The firm's fifty day moving average is $6.97 and its two-hundred day moving average is $8.16. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The company has a market cap of $193.58 million, a PE ratio of -1.44 and a beta of 2.42.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on OMER shares. StockNews.com raised shares of Omeros from a "sell" rating to a "hold" rating in a research report on Monday. D. Boral Capital reaffirmed a "buy" rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Friday. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $22.50.
Check Out Our Latest Report on OMER
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Further Reading
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
